Company newsCompany release
Viking Therapeutics VKTX
Viking Therapeutics to present two VK2735 posters at ObesityWeek 2026
The posters cover baseline characteristics from the Phase 3 VANQUISH-2 trial and the effects of VK2735 in the Phase 2 VENTURE study.
GetSignal
Viking Therapeutics said it will present two posters on its VK2735 program at The Obesity Society's Annual Meeting, ObesityWeek, held November 14 to 17, 2026, in Washington, D.C.
The first poster, on baseline characteristics of the Phase 3 VANQUISH-2 study of subcutaneous VK2735 in adults with overweight and type 2 diabetes, is scheduled for Saturday, November 14, 2026, from 7:30 pm to 8:30 pm ET in Poster Session 1. Jamy Ard, MD, FTOS, is the presenter.
The second poster, on the impact of subcutaneous VK2735 on obesity severity and cardiometabolic parameters in the Phase 2 VENTURE study, is scheduled for Sunday, November 15, 2026, from 2:30 pm to 3:30 pm ET in Poster Session 2. Harold Bays, MD, MFOMA, FTOS, FACC, FNLA, FASPC, DABOM, is the presenter. Both posters are in Exhibit Hall BCD at the Gaylord National Resort & Convention Center.
Viking Therapeutics said VK2735 is a dual agonist of the GLP-1 and GIP receptors. According to the company, it is developing VK2735 in subcutaneous and oral formulations for various metabolic disorders, including obesity.
Key facts
- Meeting
- ObesityWeek 2026, November 14 to 17, 2026, Washington, D.C.
- Poster 1 title
- VANQUISH-2 SC VK2735 Study in Adults With Overweight and Type 2 Diabetes: Baseline Characteristics
- Poster 2 title
- Impact of SC VK2735 on Obesity Severity and Cardiometabolic Parameters in the VENTURE Study
- Location
- Exhibit Hall BCD, Gaylord National Resort & Convention Center
Source: The company's release on PR Newswire, November 9, 2026.
Written by GetSignal with AI from the company's press release. How we make news
Not investment advice.
More company news
Viking Therapeutics first, then the newest- Viking Therapeutics shares VK2735 obesity trial analysis at ObesityWeek 2026
VKTX · Viking Therapeutics · Company release · Nov 15, 2026
- Canadian Natural Resources agrees to acquire Advantage Energy
CNQ · Canadian Natural Resources · Company release · Nov 16, 2026
- Rio Tinto, BCL and ABG agree to establish fund for Panguna mine legacy impacts
RIO · Rio Tinto Group · Company release · Nov 16, 2026
- CVS Health study finds GLP-1 medical savings do not fully offset pharmacy spending at current prices
CVS · CVS Health · Company release · Nov 15, 2026
- Rocket Lab reaches 100 Electron launches
RKLB · Rocket Lab · Company release · Nov 14, 2026
